ELOVL7 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-91349
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
1 mg/ml
Product Specifications
Immunogen
Synthetic peptide directed towards the N terminal of human ELOVL7. Peptide sequence MAFSDLTSRTVHLYDNWIKDADPRVEDWLLMSSPLPQTILLGFYVYFVTS. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for ELOVL7 Antibody
![Western Blot: ELOVL7 Antibody [NBP1-91349]](https://resources.bio-techne.com/images/products/ELOVL7-Antibody-Western-Blot-NBP1-91349-img0003.jpg "Western Blot: ELOVL7 Antibody [NBP1-91349]")
Western Blot: ELOVL7 Antibody [NBP1-91349]
Western Blot: ELOVL7 Antibody [NBP1-91349] - Titration: 1.25ug/ml Positive Control: HepG2 cell lysate.Applications for ELOVL7 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: ELOVL7
Alternate Names
ELOVL family member 7, elongation of long chain fatty acids, ELOVL fatty acid elongase 7
Gene Symbol
ELOVL7
UniProt
Additional ELOVL7 Products
Product Documents for ELOVL7 Antibody
Product Specific Notices for ELOVL7 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...